Drug intelligence / Profile preview

RS-007

Development stage: Preclinical
Lead developer: Related Sciences

Overview

RS-007 is a preclinical-stage therapeutic candidate being developed by Related Sciences for the treatment of autoimmune and inflammatory diseases. The program is currently in the IND-enabling phase of development. RS-007 was identified and designed using Related Sciences' data science-driven drug discovery platform, which integrates machine learning and predictive models to select high-probability target-disease opportunities.

Targets

AMPK (Adenosine monophosphate–activated protein kinase)Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on RS-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RS-007.

Explore the full profile